180 Life Sciences Current ratio
Was ist das Current ratio von 180 Life Sciences?
Current ratio von 180 Life Sciences Corp. ist 0.58
Was ist die Definition von Current ratio?
Das derzeitige Verhältnis ist ein Liquiditätsgrad das misst, ob ein Unternehmen über ausreichende Ressourcen verfügt, um seine kurzfristigen Verpflichtungen zu erfüllen.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences
Was macht 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Unternehmen mit current ratio ähnlich 180 Life Sciences
- Unitil hat Current ratio von 0.58
- Troy Income & Growth Trust Plc hat Current ratio von 0.58
- Electrotherm (India) hat Current ratio von 0.58
- Nuveen S&P 500 Dynamic Overwrite Fund hat Current ratio von 0.58
- BlueRock Diamonds PLC hat Current ratio von 0.58
- Dekel Agri-Vision plc hat Current ratio von 0.58
- 180 Life Sciences hat Current ratio von 0.58
- Old Republic International hat Current ratio von 0.59
- Pimco Income Strategy Fund II hat Current ratio von 0.59
- Esprit hat Current ratio von 0.59
- Blue Thunder Mining hat Current ratio von 0.59
- International Stem Cell hat Current ratio von 0.59
- Cathedra Bitcoin Inc hat Current ratio von 0.59